NCT06482541Phase 1Status unknown
Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia
1-Year Double-Blind Placebo-Controlled Study To EVALUATE THE EFFECT OF AGE ZERO™ EXOSOMES ON HAIR REGROWTH IN HEALTHY MEN AND WOMEN WITH ANDROGENETIC ALOPECIA
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 1
- Sponsor
- Levit Dermatology
- Participants (registry)
- 100
- Start
- July 2024
- Primary completion
- July 2025
- Study completion
- August 2025
- Last registry update
- July 2024
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: 5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.